Stifel expects buyers of Revolution Medicines (RVMD) to step into the stock on weakness after the Wall Street Journal reported that Merck (MRK) is no longer in discussions to acquire the company. Stifel would be surprised to see the stock settle meaningfully below $100 per share. This “M&A clearing event will be viewed as a buying opportunity for many sector specialists,” the analyst tells investors in a research note. The firm expects investor focus to shift now to Revolution’s “catalyst rich” 2026. It keeps a Buy rating on the shares with a $170 price target.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Merck no longer in talks to acquire Revolution Medicines, WSJ reports
- Revolution Medicines price target raised to $170 from $85 at Stifel
- Revolution Medicines price target raised to $140 from $77 at RBC Capital
- Revolution Medicines price target raised to $160 from $92 at Guggenheim
- Private Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B